India, Aug. 27 -- Roivant Sciences Ltd (ROIV), a biopharmaceutical company, on Thursday received approval from the U.S. Food and Drug Administration (FDA) for LISRAYA 30 mg in treating adult patients of dermatomyositis.
Dermatomyositis (DM) is a rare autoimmune disorder that causes muscle weakness and painful, pruritic skin lesions. The disease may severely impair a patient's quality of life, causing cutaneous disfigurement and extensive sensitivity to light and touch. Affected individuals often grow dependent on a chronic high dose of steroids.
LISRAYA (brepocitinib) is a first-in-class potent, small-molecule inhibitor of TYK2/JAK1 that has shown a high efficacy in DM patients by reducing the extent of skin disease, muscle weakness, and ...